norclozapine

04/01/2015 - "The aims of the study were to explore the association of clozapine+ norclozapine serum concentration and other factors with subjective side-effects in schizophrenia patients. "
11/01/2017 - "N-Desmethylclozapine level and ANC significantly correlated in this real-life population of schizophrenia patients. "
11/01/2017 - "Correlation Between Serum Concentrations of N-Desmethylclozapine and Granulocyte Levels in Patients with Schizophrenia: A Retrospective Observational Study."
12/25/2016 - "To investigate the effects of CLNAZ co-medication, patient gender, age and CLZ dosage on serum concentration of CLZ and norclozapine (N-CLZ) in individuals with schizophrenia. "
09/01/1994 - "Adolescents with schizophrenia produce a greater amount of desmethylclozapine than previously seen in adults. "

06/01/2022 - "Adverse drug reactions are caused by both CLO and its primary metabolite, norclozapine (NCLO). "
01/01/2012 - "Decreased clearance of clozapine and norclozapine with age results in increased blood concentrations and, hence, the potential for adverse drug reactions. "
03/01/2021 - "A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions."

05/01/1997 - "The aim of this open study was to determine a more rational therapeutic approach for psychotic patients treated with clozapine for several months, using measurement of plasma and red blood cell levels (P, RBC) of clozapine (cloza) and N-desmethylclozapine (descloza), the major metabolite of clozapine, which has been reported to be less active but more toxic (agranulocytosis) than clozapine itself. "
08/01/1994 - "In this study, plasma levels of clozapine and desmethylclozapine were measured in five patients who developed agranulocytosis. "
11/01/1997 - "N-desmethylclozapine, an insensitive marker of clozapine-induced agranulocytosis and granulocytopenia."
08/01/1994 - "Plasma clozapine and desmethylclozapine levels in clozapine-induced agranulocytosis."
03/01/1994 - "Bone marrow from patients with acute clozapine-induced agranulocytosis was not more sensitive to clozapine or N-desmethylclozapine than bone marrow from normal donors. "

03/01/2023 - "The effect of dose, sex, ethnicity, age, body weight, and smoking habit on plasma clozapine and norclozapine concentrations were studied using data from a therapeutic drug monitoring service, 1993 to 2017. "
01/01/2022 - "Body weight gain in clozapine-treated patients: Is norclozapine the culprit?"
05/01/2013 - "Multiple linear regression analysis was performed to investigate the relationship between plasma clozapine concentration and dose, age, sex, body weight, plasma clozapine:norclozapine ratio (clozapine metabolic ratio (MR)) and smoking habit. "
02/01/2004 - "In 4963 (50.2 %) samples (2222 patients); plasma clozapine concentration ranged from 10 to 350 ng/mL.Step-wise backward multiple regression analysis (37 % of the total samples) of log10 plasma clozapine concentration against log10 clozapine dose (mg/d), age (year), sex (male = 0, female = 1), cigarette smoking habit (nonsmokers = 0; smokers = 1), body weight (kg), and plasma clozapine/norclozapine ratio (clozapine metabolic ratio, MR) showed that these covariates explained 48% of the observed variation in plasma clozapine concentration (C = ng/mL x 10-3) (P < 0.001) according to the following equation: log 10 (C) = 0.811 log 10 (dose) + 0.332 (MR) + 69.42 X 10 (-3) (sex) + 2.263 x 10 (-3) (age) + 1.976 x 10(-3) (weight) - 0.171 (smoking habit) - 3.180. "
04/01/2002 - "Daily doses (milligrams per kilogram of body weight) of clozapine correlated positively with clozapine plasma parameters, except with the norclozapine/clozapine ratio, in all patients. "

09/01/2008 - "The clozapine metabolite N-desmethylclozapine (NDMC) has shown some promise as an alternative or adjunct treatment for psychotic disorders. "
11/11/2003 - "As hypofunction of N-methyl-d-aspartate (NMDA) receptor-driven neuronal ensembles has been implicated in psychotic disorders, the neuronal activity of N-desmethylclozapine was electrophysiologically investigated in hippocampal rat brain slices. "
02/01/1995 - "The purpose of this study was to determine the plasma level of clozapine and its metabolite, N-desmethylclozapine, in Parkinson's disease patients with L-DOPA-induced psychosis responsive to clozapine. "